Scryb Inc.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2025, AND 2024

(Expressed in Canadian Dollars)

Dated: August 29, 2025

Management's Discussion and Analysis of Operations

For the nine-months ended June 30, 2025, and 2024

This Management's Discussion and Analysis ("MD&A") is prepared for the nine months ended June 30, 2025, and 2024 and has been prepared in accordance with International Financial Reporting Standards ("IFRS"). All amounts are in Canadian dollars.

Management is responsible for the preparation and integrity of the financial statements, including the maintenance of appropriate information systems, procedures and internal controls and to ensure that information used internally or disclosed externally, including the financial statements and MD&A, is complete and reliable. The Company's directors follow recommended corporate governance guidelines for public companies to ensure transparency and accountability to shareholders. The board's audit committee meets with management quarterly to review the financial statements including the MD&A and to discuss other financial, operating and internal control matters.

Caution Regarding Forward Looking Statements

This document contains forward-looking statements, such as statements regarding future sales opportunities in various global regions and financing initiatives that are based on current expectations of management. These statements involve uncertainties and risks, including the Company's ability to obtain and/or access additional financing with acceptable terms, and delays in anticipated product sales. Such forward-looking statements should be given careful consideration and undue reliance should not be placed on these statements.

The preparation of the MD&A may require management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Management bases estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Management believes the accounting policies, outlined in the Material Accounting Policies section of its consolidated financial statements, affect its more significant judgments and estimates used in the preparation of its consolidated financial statements.

Introduction

The following MD&A for the nine-months ended June 30, 2025 and 2024 has been prepared to help investors understand the financial performance of Scryb Inc. ("the Company" or "Scryb"), in the broader context of the Company's strategic direction, the risk and opportunities as understood by management, and the key metrics that are relevant to the Company's performance. The Audit Committee of the Board of Directors has reviewed this document and all other publicly reported financial information for integrity, usefulness, reliability and consistency. All amounts are expressed in Canadian dollars (CAD) unless otherwise noted.

Additional information about Scryb Inc., this document, and the related quarterly financial statements can be viewed on the Company's website at *www.scryb.ai* and are available on SEDAR+ at *www.sedar.com*. The Company's Common Shares are listed and traded on the Canadian Securities Exchange ("CSE").

Overview

Scryb invests in and actively supports a growing portfolio of innovative and high-upside ventures across AI, biotech, digital health, and cybersecurity. Our core strategy is to identify high-growth opportunities, develop breakthrough technologies, and rapidly scale these ventures to achieve commercial success. Our diversified portfolio is anchored by investments in leading companies such as Cybeats Technologies Corp., Glow LifeTech Corp., our recently divested joint venture interest in Fionet Rapid Response Group (FRR Group) and Raidian, an AI governance platform designed to address the emerging regulatory needs in the AI sector.

Cybeats Technologies Corp.

Ownership & Accounting

Scryb holds approximately 64.5 million common shares and has loaned approximately $2.4 million in advances to assist with the ongoing working capital needs as of Cybeats as of the period ended June 30, 2025. Upon the completion of a debt settlement, along with a private brokered offering of Cybeats as of the filing date August 29, 2025, Scryb owns over 74.4 million common shares representing a 38.59% ownership of the issued and outstanding common shares of Cybeats. Cybeats has reduced its advances owing to Scryb through the debt settlement and has made cash repayments amounting to $250,000 subsequent to the period ended June 30, 2025. As of the date of filing August 29, 2025, Scryb holds a $1.2 million receivable from Cybeats.

Following the Cybeats financing which closed on November 29, 2024, Scryb no longer maintains control over Cybeats from an accounting perspective and now accounts for its investment on a passive, equity-method basis. Since the reverse takeover transaction on November 11, 2022, which took Cybeats public, Scryb has maintained an ownership interest in Cybeats in excess of 50%. Accordingly for accounting purposes it was considered that Scryb controlled Cybeats and the full operating results and balance sheet of Cybeats have historically been consolidated into the financial statements of Scryb.

On November 29, 2024 Cybeats closed the first tranche of a financing resulting in a dilution of Scryb's 50.92% ownership in Cybeats to 49.23%. For accounting purposes this is considered a loss of control in Cybeats, and the accounting rules require that Scryb would no longer consolidate Cybeats. Scryb would carry Cybeats on its balance sheet using the equity method of accounting from the date control ceases. Such rules also require that the investment in Cybeats be revalued to fair market value on the date control ceases. The deemed fair market value for accounting purposes of Scryb's investment in Cybeats was $0.15 per share resulting in a total investment in Cybeats of $9.0m. This value does not necessarily reflect Scryb management's view on the long-term value of its investment in Cybeats.

Scryb strategically invested $500,000 in Cybeats' private placement on November 29, 2024, at $0.16 per share and further increased its position by acquiring over 300,000 common shares in February 2025. This move underscores Scryb's strong confidence in Cybeats' long-term growth potential, particularly given the company's impressive commercial progress, which includes a 148% net revenue retention rate, multi-year contracts with industry leaders such as Schneider Electric and Rockwell Automation, over $7 million in total multi-year contract commitments, and a 90% conversion rate from trial programs to commercial licenses. Scryb's investment reflects its continuing commitment to supporting high-growth opportunities and driving long-term shareholder value through strategic capital deployment.

Market

In May 2021, U.S. policymakers designated cybersecurity as a national priority, mandating that federal systems exceed prescribed standards. A key requirement was the implementation of a Software Bill of Materials (SBOM) to enhance supply chain integrity—a solution integral to Cybeats' SBOM Studio. Since then, regulators worldwide, including the FDA and other Western governments, have adopted SBOM standards to mitigate software supply chain risks, a trend reinforced on July 13, 2023, when the White House included SBOMs as a pillar in the National Cybersecurity Strategy Implementation Plan.

As modern software relies on open-source software (OSS) components—present in 99% of applications—organizations face significant cybersecurity risks, with studies showing that 75% of OSS contains vulnerabilities. With cyberattacks exploiting these weaknesses growing each year, high-profile incidents like the *log4j* and *SolarWinds* breaches underscore the critical need for continuous SBOM monitoring to safeguard software supply chains.

Commercial Traction

As of June 30, 2025, Cybeats secured several multi-year enterprise engagements valued in the six to seven-figure range across diverse industry verticals. In the medical device and technology sector, the Company has secured contracts with multiple leading organizations—including three of the top seven medical device manufacturers globally—demonstrating robust market validation for its SBOM Studio. Additionally, significant engagements have been established with major industrial control system providers such as Schneider Electric SE and Rockwell Automation, along with key contracts in sectors including regulated cryptocurrency exchanges, telecommunications, and government agencies.

These contracts are underpinned by targeted marketing initiatives that generate high-quality leads and drive focused follow-up by our business development team. This disciplined approach has contributed to an 83% monthly recurring revenue growth and over 148% net revenue retention for SBOM Studio in 2024, underscoring the effectiveness of our commercial strategy and the high value of our recurring revenue base.

Glow LifeTech Corp.

Glow LifeTech ("Glow"), a publicly traded company on the CSE under the symbol "GLOW" was formerly a subsidiary of Scryb and was spun out into its own public company through an RTO transaction on March 15, 2021. Scryb played a critical role in the go-public transaction. Glow is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption, and effectiveness. Glow has rights to the innovative, plant-based *MyCell*™ Technology delivery system, which transforms poorly absorbed natural compounds into enhanced water-compatible concentrates, unlocking the full healing potential of natural active compounds.

Glow launched two cannabis consumer brands in Canada, *MOD* and *.decimal*, with both featuring Glow's portfolio of proprietary liquid and powder cannabis ingredient technologies. *MOD* is a brand of naturally flavoured water-soluble drops and *.decimal* is a brand of precision-dosed, fast-acting capsules.

As of the filing date August 29, 2025, Glow has secured a new retail listing with FIKA Company bringing *MOD* products to approximately 100+ FIKA Company retail locations across Ontario. Glow is well positioned and supported in the marketplace as this listing marks a significant milestone in the expansion of *MOD*, deepening its retail penetration in Ontario.

Raidian Inc.

Raidian aims to improve the safety and trustworthiness of Artificial Intelligence, as well as the evaluation, development, and implementation of all AI products and solutions at an organization. This product anticipates the global trend of increasing AI adoption and the impending need for effective management solutions. Further investment by Scryb into the Raidian business have been temporarily paused as the Company evaluates its strategic options related to Raidian. The Raidian leadership team will continue to seek funding and partnerships that can support the growth of company.

Fionet Rapid Response Group

On December 6, 2024, Scryb completed the divestiture of its joint venture interest in FRR Group to a private corporate development company for total fixed proceeds of $3.5 million, inclusive of debt repayment. As of this filing, the full $3.5 million has been received, along with a one-time payment of $100,000 to satisfy any future royalty obligations owed by Fio Corp. through the original agreement's end date of December 31, 2025. This divestiture allowed Scryb to redeploy capital into higher-value opportunities while maintaining non-competitive access to FRR Group's technology.

Financing, Capital Structure, and Cost Management

On January 31, 2025, Scryb successfully completed a secured convertible debenture offering led by Plaza Capital, raising gross proceeds of $1,175,300. The debentures carry an annual interest rate of 12% and are convertible at $0.05 per share, with a two-year maturity (one-year maturity for the lead investor debenture). This financing enhances the Company's liquidity and supports growth initiatives. Additionally, on February 2, 2025, the Company settled $116,700 in outstanding debts through the issuance of 2,334,000 common shares at $0.05 per share, preserving cash for working capital.

Subsequent to the period ended June 30, 2025, Cybeats completed a successful LIFE offering with gross proceeds of $3,237,000 issuing 32,370,000 common shares at a unit price of $0.10. In the near- to medium-term, Scryb believes Cybeats is well positioned to improve its working capital, scale its commercial activities, and further its development process. This ensures that Scryb maintains a strong investment position in Cybeats as it pursues new opportunities.

With Cybeats having closed a LIFE Offering on August 10, 2025, Cybeats has a strong balance sheet and is well positioned financially. Scryb has a strong balance sheet and high net asset values, and is in a strong position to raise new capital on the equity markets.

Outlook

Scryb's diversified portfolio positions Scryb to leverage emerging trends and capitalize on new opportunities. We remain actively engaged in exploring additional investments that align with our growth strategy. Looking ahead, we are committed to further optimizing our cost structure, expanding our portfolio, and ensuring that our capital is deployed in initiatives with the highest potential for long-term value creation. Our recent financing activities and portfolio realignments are integral to this strategy.

As of August 29, 2025, Scryb Inc. remains well-positioned as a leading venture builder in the technology sector. Through strategic investments in high-growth companies such as Cybeats and Glow LifeTech, the divestiture of our interest in FRR Group, and the launch of Raidian, we are driving long-term shareholder value. Our recent financing activities, including the convertible debenture offering, combined with disciplined cost management, have further strengthened our financial position. We continue to pursue additional investment opportunities and operational efficiencies to sustain our growth trajectory.

Selected Annual Information

The following table sets forth selected financial information for Scryb Inc. for the three and nine-months ended June 30, 2025. This information has been derived from the Company's financial statements for the years and should be read in conjunction with the financial statements and notes thereto.

	For the three months ended June 30, 2025	For the three months ended June 30, 2024	For the nine months ended June 30, 2025	For the nine months ended June 30, 2024
Revenues	107,683	485,657	346,286	1,461,832
Expenses	554,047	4,070,509	3,543,753	11,586,847
Net Income (Loss) and Other Comprehensive Income (Loss)	(1,237,620)	(4,008,357)	5,489,617	(10,951,490)
Net Income (Loss) per Common Share	(0.00)	(0.01)	0.02	(0.04)
Total Assets	11,701,916	9,346,296	11,701,916	9,346,296
Total Liabilities	2,878,577	9,690,039	2,878,577	9,690,039
Working Capital	(778,369)	(5,345,755)	(778,369)	(5,345,755)

Figures presented above include the revenues and expenses of Cybeats under the principals of consolidation while the Company held a 51% controlling interest in Cybeats and up to the date of control ceased which ceased on November 29, 2024.

The Company recognized a $9.23 million accounting gain following the cessation of control of Cybeats and subsequent deconsolidation dated November 29, 2024. Prior period figures also include consolidated revenues and expenses for Cybeats under the previously discussed principals of consolidation.

The following table sets forth selected financial information for Scryb Inc. for the nine-months ended ending June 30, 2025, and the years ended September 30, 2024, and 2023. This information has been derived from the Company's financial statements for the periods indicated and should be read in conjunction with audited financial statements and the notes thereto.

	Nine-months Ended 30-Jun-25	Year Ended 30-Sep-24	Year Ended 30-Sep-23
Net Income (Loss) from Operations	$ (3,197,467)	$ (12,949,288)	$ (19,632,739)
Net Income (Loss) before Income Taxes	5,489,617	(13,999,708)	(28,195,808)
Income (Loss) per Common Share, Basic and Diluted	0.02	(0.04)	(0.08)
Net Income (Loss) and Other Comprehensive Income (Loss)	5,489,617	(13,999,708)	(28,195,808)
Net Income (Loss) per Common Share, Basic and Diluted	0.02	(0.04)	(0.08)
Weighted Average Number of Shares Outstanding	318,193,090	268,605,208	248,111,312
Total Assets	11,701,916	8,804,673	12,045,959
Net Working Capital	(778,369)	(5,958,334)	(1,733,389)

Figures presented above include the revenues and expenses of Cybeats under the principals of consolidation when the Company held a 51% controlling interest in Cybeats up to the date of control ceased; November 29, 2024.

For the three months ended June 30, 2025, and 2024

The schedule below presents the three-month statement of earnings with a net loss of $1,237,620 (June 30, 2024 – loss of $4,008,357).

	Three months ended		
	June 30, 2025	**June 30, 2024**	**Variance**
Revenues			
Product sales	-	475,657	(475,657)
Royalty revenues	100,000	-	100,000
Other revenues	7,683	10,000	(2,317)
	107,683	**485,657**	**(377,974)**
Expenses			
Professional & consulting fees	168,899	271,871	(102,971)
Salaries and wages	139,004	1,812,571	(1,673,566)
Research & development in Raidian Joint Venture	109,261	-	109,261
Product research and development costs	-	270,255	(270,255)
Amortization and depreciation	23,963	80,939	(56,976)
Interest and accretion	66,236	478,649	(412,413)
Insurance expenses	14,392	30,768	(16,375)
Share-based compensation	-	376,847	(376,847)
Investor relations, advertising, and marketing	4,933	598,482	(593,550)
General, administrative, and other expenses	26,889	116,957	(90,067)
Foreign currency (gain) loss	468	33,171	(32,703)
	554,047	**4,070,509**	**(3,516,462)**
Net Income (Loss) from Operations	**(446,364)**	**(3,584,852)**	**3,138,488**
Non-cash - Equity share of loss in Cybeats after change in control	433,652	-	433,652
Non-cash - Unrealized loss on investment in Glow LifeTech Corp.	156,680	444,033	(287,353)
Non-cash - Debt forgiveness	(92,552)	(20,528)	(72,024)
Non-cash - Non-recurring settlement fees	204,000	-	204,000
Net (gain) loss on sale of investments	89,475	-	89,475
Net Income (Loss) and Comprehensive Income (Loss)	**(1,237,620)**	**(4,008,357)**	**2,770,738**

Certain expenses have been reclassified to conform with the current presentation.

Figures presented in the prior period comparatives include the revenues and expenses of Cybeats under the principals of consolidation when the Company held a 51% controlling interest in Cybeats.

- Product sales in the comparative period include revenues from Cybeats which are not present in the current period post consolidation.
- Royalty revenues comprise of a one-time $100,000 royalty from the FRR JV which voids any future royalty obligations owed by Fio Corp. through the original agreement's end date of December 31, 2025.
- Other revenues include revenues generated from management services provided to FRR before the divestiture, coupled with expense recovery of shared office spaces.
- Professional & consulting fees decreased from $271,871 to $168,899 in the current period, due to cost cutting measures to focus on core operations in the current period.
- Salaries and benefits declined from $1.81 million to $0.14 million, driven primarily from the deconsolidation with Cybeats on November 29, 2024, coupled with efforts to reduce overhead expenditures by the Company.
- Product development costs have decreased during the period following the cease of control of Cybeats.

- Amortization and depreciation expense decreased due to a lease modification for Scryb.

- Interest and accretion expenses in the current period include an interest expense of the convertible debenture issued by the Company. In the prior period, interest and accretion was also driven by the convertible debenture issued by Cybeats.

- Share-based Compensation expenses include options issued to various directors, employees, consultants during the period.

- Investor relations, advertising, and marketing expenses in the prior period include marketing costs incurred by Cybeats which is not present in the current period.

- General, administrative, and other expenses relate to continued corporate infrastructure, maintenance, and issuer fees. Costs associated with maintaining the services have declined due to the deconsolidation with Cybeats.

- Foreign currency gains occurred before Cybeats' deconsolidation, driven by USD-denominated sales and favorable USD:CAD exchange rates.

- Debt forgiveness amounts in the current year relate to certain suppliers agreeing to cancel or waive long term outstanding balances.

- Non-recurring settlement fees represent the settlement of amounts owing to former employees of the Company upon separation.

- The Company's equity share of loss in Cybeats after change in control is the partial period equity losses of Cybeats after the partial period consolidation.

- The Company recorded $156,680 in unrealized gains on the fair value of its holdings of Glow LifeTech common shares in the current period.

- The Company recognized approximately $89,000 losses from the sale of common shares held in its investment in Glow LifeTech.

For the nine months ended June 30, 2025, and 2024

The schedule below presents the nine-month statement of earnings with a net income of $5,489,617 (June 30, 2024 – loss of $10,951,490).

	Nine months ended		
	June 30, 2025	**June 30, 2024**	**Variance**
Revenues			
Product sales	208,437	1,292,726	(1,084,289)
Royalty revenues	100,000	118,914	(18,914)
Other revenues	37,849	50,193	(12,344)
	346,286	**1,461,832**	**(1,115,546)**
Expenses			
Professional & consulting fees	1,227,292	530,718	696,574
Salaries and wages	828,697	5,298,424	(4,469,728)
Research & development in Raidian Joint Venture	300,000	-	300,000
Product research and development costs	215,239	909,539	(694,299)
Amortization and depreciation	328,200	875,483	(547,283)
Interest and accretion	319,531	749,266	(429,736)
Insurance expenses	41,892	62,200	(20,307)
Share-based compensation	144,908	1,112,495	(967,587)
Investor relations, advertising, and marketing	51,196	1,760,111	(1,708,915)
General, administrative, and other expenses	119,509	254,467	(134,957)
Foreign currency (gain) loss	(32,711)	34,145	(66,855)
	3,543,753	**11,586,847**	**(8,043,094)**
Net Income (Loss) from Operations	**(3,197,467)**	**(10,125,015)**	**6,927,548**
Non-cash - Proportionate share of loss in FRR prior to sale	355,920	-	355,920
Non-cash - Equity share of loss in Cybeats after change in control	1,359,658	-	1,359,658
Non-cash - Unrealized loss on investment in Glow LifeTech Corp.	8,795	847,003	(838,208)
Non-cash - Debt forgiveness	(248,134)	(20,528)	(227,606)
Non-cash - Non-recurring settlement fees	410,140	-	410,140
Net (gain) on sale of investments	(1,273,467)	-	(1,273,467)
Net gain on cessation of control of Cybeats Technologies Corp.	(9,299,995)	-	(9,299,995)
Net Income (Loss) and Comprehensive Income (Loss)	**5,489,617**	**(10,951,490)**	**16,441,106**

Certain expenses have been reclassified to conform with the current presentation.

Figures presented above include the revenues and expenses of Cybeats under the principals of consolidation when the Company held a 51% controlling interest in Cybeats up to the date of control ceased; November 29, 2024.

- Product sales decreased to $208,437 from $1,292,726 impacted by a partial period consolidation with Cybeats, given the date cease of control occurred during the period.

- Royalty revenues comprise of a one-time $100,000 royalty from the FRR JV which voids any future royalty obligations owed by Fio Corp. through the original agreement's end date of December 31, 2025.

- Other revenues includes revenues generated from management services provided to FRR before the divestiture, coupled with expense recovery of shared office spaces.

- Professional & consulting fees rose from $530,718 to $1,227,292 during the period, due to the transition of in-house personnel to external consulting roles, particularly relating to the new AI governance business prior to signing the Raidian commitment. Certain professional fees; including legals and audit services, increased during the period due to services required for the sale of FRR.

- Salaries and benefits declined from $5.3 million to $0.8 million, driven primarily from the partial period consolidation with Cybeats, coupled with efforts to reduce overhead expenditures.
- Product development costs have decreased during the period following the cease of control of Cybeats.
- Amortization and depreciation expense decreased due to a lease modification for Scryb.
- Interest and accretion expenses in the current period include an interest expense of the convertible debenture issued by the Company. In the prior period, interest was also driven by the convertible debenture issued by Cybeats.
- Share-based Compensation expenses include options issued to various directors, employees, consultants during the period.
- Investor relations, advertising, and marketing expenses dropped from $1,760,111 to $51,196, reflecting cost-cutting measures by management, reduced marketing needs, and associated expenditures coupled with prior year figures including significant Cybeats advertising expenditures.
- General, administrative, and other expenses include fees relate to continued corporate infrastructure, maintenance, and issuer fees. Costs associated with maintaining these services have declined due to the deconsolidation with Cybeats.
- Foreign currency gains occurred before Cybeats' deconsolidation, driven by USD-denominated sales and favorable USD:CAD exchange rates.
- Debt forgiveness amounts in the current year relate to certain suppliers agreeing to cancel or waive long term outstanding balances.
- Non-recurring settlement represents the settlement of amounts owing to former employees of the Company upon separation.
- The Company's equity share of loss in Cybeats after change in control is the partial period equity losses of Cybeats after the partial period consolidation.
- The Company recorded $8,795 in net unrealized losses on the fair value of its holdings of Glow LifeTech common shares.
- Scryb sold its 33% ownership of the FRR JV during the period, resulting in a gain from the sale of its investment in FRR of $1.36 million. Scryb also recognized approximately $89,000 in losses from the sale of its Glow shares.
- Scryb's ownership in Cybeats fell below 50% due to dilution from the Cybeats private placement offering in November 2024, and the deconsolidation of Cybeats resulting in a gain on the cessation of control.

Summary of Quarterly Results

The following table is a summary of selected unaudited financial information for the eight most recent fiscal quarters.

Quarter ended	Revenue	Net income (loss)	Net income (loss) per share
June 30, 2025	107,683	(1,237,620)	(0.00)
March 31, 2025	13,700	(1,328,805)	(0.00)
December 31, 2024	224,903	8,056,041	0.02
September 30, 2024	380,747	(3,048,217)	(0.01)
June 30, 2024	485,657	(4,009,116)	(0.01)
March 31, 2024	492,750	(4,046,080)	(0.02)
December 31, 2023	483,425	(2,896,294)	(0.00)
September 30, 2023	782,269	(3,846,633)	(0.02)

Net loss for the quarter ended June 30, 2025, was driven by the Company's share of equity loss in Cybeats after change in control coupled with the Company's transition of in-house personnel to external consulting roles including relating to the new AI governance business development.

Funding & Liquidity

Scryb will require additional funding to fund maintain ongoing operations and growth. Future cash will be financed through share capital, receivables, as well as leveraging assets or from the disposition of assets. Scryb also has opportunities to partially divest some of its investments.

Related Party Transactions

Scryb is a non-controlling related party of Cybeats. Scryb has, from time to time, loaned funds to Cybeats for a net total amount of $2,262,238 (the "Cybeats Loan") as of June 30, 2025.

Included in the above, effective January 31, 2025, Scryb has also assumed the obligations of Cybeats to a related party in the amount of $614,116 (the "Assumed Debt") owing to 2013025 Ontario Inc. (a company controlled by a director of Scryb). In tandem with the assumption of debt, Cybeats issued a promissory note to Scryb for the amount of the Assumed Debt. The aggregate outstanding amounts owed by Cybeats to Scryb are included in a secured non-convertible debenture at interest rate of 10% per annum, and matures on October 14, 2025. The above loan arrangements between Scryb and Cybeats are secured by way of a general security agreement.

As of the period ended June 30, 2025, the Scryb owed 2013025 Ontario Inc. (a company controlled by a director of Scryb) interest bearing loans with no fixed terms of repayment in the amount of $557,943 (September 30, 2024 – $747,400). The outstanding amount is inclusive of the above-mentioned debt assumption on January 31, 2025 whereby Scryb assumed the $614,116 owing to 2013025 Ontario Inc. from Cybeats. This loan bears interest at 18% per annum, is due and payable on demand.

Subsequent to the period ended June 30, 2025, Scryb acquired 9,788,450 common shares of Cybeats in settlement of $948,845 of debt. After completion of the debt settlement, and the brokered offering of Cybeats that closed on August 5, 2025, and August 7, 2025, respectively, Scryb holds over 74.4 million common shares approximately 38.59% of the issued and outstanding common shares of Cybeats.

Off-Balance Sheet Arrangements

The Company has not entered into any off-balance sheet arrangements, other than previously disclosed, that has, or is reasonably likely to have, an impact on the current or future results of operations or the financial condition of our company.

Critical Accounting Policies and Estimates

The preparation of these consolidated financial statements in conformity with IFRS requires that management make estimates and assumptions about future events that affect the amounts reported in the consolidated financial statements and related notes to the consolidated financial statements. Actual results may differ from those estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

i) Critical accounting estimates

Critical accounting estimates are estimates and assumptions made by management that may result in a material adjustment to the carrying amount of assets and liabilities within the next financial year and are, but are not limited to, the following:

Share based payments and warrants

The fair value of stock options and warrants issued are subject to the limitation of the Black Scholes option pricing model that incorporates market data and involves uncertainty in estimates used by management in the assumptions. Because the Black Scholes option pricing model requires the input of highly subjective assumptions, including the volatility of share prices, changes in subjective input assumptions can materially affect the fair value estimate.

Useful life of intangible assets

Management has exercised their judgment in determining the useful life of its patents, patent applications and software license. The estimate is based on the expected period of benefit of the patent and the expected life of the product in the marketplace.

ii) Critical accounting judgments

Information about critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements are, but are not limited to, the following:

Accounting for investments

Management determined that effective November 29, 2024, the Company had lost control of Cybeats and accordingly changed from the consolidation method of accounting to the equity method of accounting.

Evaluation of going concern

The preparation of the financial statements requires management to make judgments regarding the going concern of the Company.

Income taxes

Management has exercised their judgment in determining the provision for future income taxes. The judgment is based on the Company's current understanding of the tax law as it relates to the transactions and activities entered into by the Company.

Research vs. Development Stage

The Company uses judgement when assessing if the Company has achieved development stage activities with its internally generated intangible assets.

Risks and Uncertainties

History of Losses – The Company has been in a cumulative net loss position throughout its operating history. The Company's limited operating history makes it difficult to evaluate the future financial prospects of its business. There is no assurance that the Company will grow or be profitable or that the Company will have earnings or significant improvement in its cash flow from operations in the future. The future earnings on and cash flow from operations are dependent on the Company's ability to further develop and sell its products and the Company's operational expenses. Management expects that the Company will continue to have high levels of operating expenses, since the Company needs to make significant up-front expenditures for product development, and corporate development activities. Management anticipates that the operating losses for the Company may continue until such time as the Company consistently generates sufficient revenues to support operations.

Need for Additional Financing - The implementation of the Company's business plan requires significant capital outlays and operating expenditures over the next several years. There can be no assurance that additional financing will be available to the Company when needed, on commercially reasonable terms, or at all. Any inability to obtain additional financing when needed would have a material adverse effect on the Company. Further, any additional equity financing may involve substantial dilution to the Company's then existing shareholders. Debt financing, if available, may involve onerous obligations, monetary or otherwise. If adequate funds are not available, the Company may obtain funds through arrangements with strategic partners or others who may require the Company to relinquish rights to certain technologies, any of which could adversely affect its business, financial condition and results of operations.

Product Risks

Uncertain Demand for Products - Demand for technologies is dependent on a number of social, political and economic factors that are beyond the control of the Company. The technology industry is likely to continue to change as the public and government will alter regulation and demand for the products. While the Company believes that demand for technological solutions will continue to grow, there is no assurance that such demand will exist or that the Company's products will be purchased to satisfy that demand.

Dependence on Development of New Products - New technological or product developments in the technology industry may render the Company's products obsolete or reduce their value. The Company's future prospects are highly dependent on its ability to develop new products - from new technologies and achieve market acceptance. There can be no assurance that the Company will be successful in these efforts.

Credit Risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents. The Company has reduced its credit risk by investing its cash equivalents with Canadian chartered banks.

Disclosure Controls and Procedures & Internal Controls over Financial Reporting

In accordance with the Canadian Securities Administrators National Instrument 52-109 ("NI 52-109"), Certification of Disclosure in Issuers' Annual and Interim Filings, the Company has filed certificates signed by the Chief Executive Officer and the Chief Financial Officer that, among other things, report on the design and effectiveness of disclosure controls and procedures and the design and effectiveness of internal controls over financial reporting.

The Company continues to review and document its disclosure controls and procedures and internal controls over financial reporting and may, from time to time, make changes aimed at enhancing their effectiveness and to ensure that its systems evolve with the business. There were no changes in the Company's internal controls over financial reporting during the period ended June 30, 2025, that have materially affected, or are reasonably likely to materially affect, its disclosure controls and procedures and internal controls over financial reporting.

Share Data

As at June 30, 2025, there were 323,187,472 common shares issued and outstanding, 64,722,000 warrants, and 39,575,000 options outstanding.

As at August 29, 2025, there were 323,187,472 common shares issued and outstanding, 64,722,000 warrants, and 32,225,000 options outstanding.

"James Van Staveren"

Chief Executive Officer

August 29, 2025